Compare Marvell Technology Inc (MRVL) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marvell Technology Inc vs Novartis AG — how do they compare? Marvell Technology Inc trades at $222.29 (market cap $190.56B), while Novartis AG trades at $153.29 (market cap $295.37B). The key difference: Novartis AG is the larger of the two by market cap, and Novartis AG pays the higher dividend (3.07%). Which is the better fit depends on your goals.
| MRVL | NVS | |
|---|---|---|
Market Cap | $190.56B | $295.37B |
Sector | Technology | Health |
52-Week High | $316.43 | $168.62 |
52-Week Low | $62.31 | $119.31 |
Enterprise Value | $191.99B | $336.69B |
Dividend Yield | 0.11% | 3.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Marvell Technology (MRVL) trades at $208.56, down 4.65% on the day, amid a broader semiconductor sell-off. The stock shows a bullish technical signal with support near $201 and resistance at $223. Fundamentally, while recent quarters have seen EPS beats, the company reported a net loss of $885 million for 2025, though revenue grew to $5.77 billion. Analyst sentiment remains strongly positive with an 82% buy rating and a $275.68 consensus price target, citing AI infrastructure growth drivers.
The outlook for MRVL is supported by its positioning in AI data center and optical networking markets, with partnerships like NVIDIA and Microsoft's Maia 300 offering significant upside. Key risks include intense competition, margin pressures, and geopolitical supply chain disruptions. Investors should weigh the high valuation multiples against the potential for AI-driven revenue acceleration in 2026.
Novartis AG (NVS) trades at $156.79, up 0.29% today, with a bullish technical signal from moving averages and recent Q2 2026 earnings beating estimates. Strong profitability is evident with a 74.74% gross margin and 22.5% net margin, while revenue grew to $56.67B in 2025. The stock faces resistance near $157, with support at $156.
The outlook is positive due to robust drug pipeline progress and reaffirmed 2026 guidance, though risks include generic competition for Entresto and pricing pressures. Analyst sentiment is mixed with 24% buy ratings, but institutional buying activity supports confidence in long-term growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Marvell Technology Inc
Marvell Technology is a leading fabless chipmaker focused on networking and storage applications. Marvell serves the data center, carrier, enterprise, automotive, and consumer end markets with processors, optical interconnections, application-specific integrated circuits (ASICs), and merchant silicon for Ethernet applications. The firm is an active acquirer, with five large acquisitions since 2017 helping it pivot out of legacy consumer applications to focus on the cloud and 5G markets.
Read more on MRVL →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
